RecruitingNCT06100718

Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study


Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

370 participants

Start Date

Jan 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

INVISIBLE-1 aims to prospectively follow patients up to one year after ischemic stroke to: 1. Determine the cumulative incidence of occult cancer in patients with embolic stroke of undetermined source (ESUS) and elevated D-dimer 2. Describe occult cancer characteristics and spontaneous course of occult cancer Methodology The investigators will include 370 stroke patients with elevated D-dimer (≥ 820 μg/L) at the time of stroke, suspicion of ESUS after initial workup and without known cancer. The investigators will perform a follow-up telephone interview at one year to assess the occurrence of a new cancer and characterize the course of the disease. Significance Determining the real incidence of occult cancer in high-risk patients will help support the implementation of screening trials in the future. Faster detection and treatment of occult cancers would significantly impact patient' outcomes by offering faster cancer treatment and optimal secondary stroke prevention.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study — called INVISIBLE-1 — is following people who had a stroke of unknown cause (called an embolic stroke of undetermined source, or ESUS) to check whether they may have an undetected cancer in the year after the stroke. Researchers believe some unexplained strokes may be an early sign of hidden cancer. **You may be eligible if...** - You are 18 years or older - You have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) with symptoms starting within 48 hours before coming to the hospital - After initial workup, the cause of the stroke remains unknown (ESUS — no detected atrial fibrillation, large vessel blockage, or other obvious cause) - A blood test taken shortly after your stroke showed an elevated D-dimer level (a clotting marker often elevated with cancer) **You may NOT be eligible if...** - You already have a known active cancer diagnosis - You were given clot-busting treatment (thrombolysis) before the D-dimer blood test was taken - You have been newly diagnosed with a brain cancer - You or your family are unlikely to be able to complete follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(3)

Dept. of Neurology, Centre Hospital Universitaire Vaudois

Lausanne, Canton of Vaud, Switzerland

Dept. of Neurology, Universitätsspital Basel

Basel, Switzerland

Dept, of Neurology, Inselspital, University of Bern

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06100718


Related Trials